28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our findings suggest that VILIP-1 may play a role in the AD pathophysiology and is a good candidate for dynamic biomarker of AD, although this issue requires further investigation. 3 key findings →
Participants: 33 Evidence: low
Full summary, score breakdown and related studies → Original source
Depressed individuals are twice as likely to develop Alzheimer's disease (AD) as compared to controls. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Gait disturbances are some of the earliest changes in dementia and their monitoring presents an opportunity for early diagnosis. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma amyloid β-42 (Aβ42) and Aβ42/Aβ40 are increasingly recognized as biomarkers for dementia, with low levels indicating increased risk. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
CD22 has been suggested to contribute to Alzheimer's disease (AD) pathogenesis by inhibiting microglial amyloid β (Aβ) phagocytosis. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common form of cognitive decline worldwide, occurring in about 10% of people older than 65 years. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Treatment with the ABCA1 agonist CS-6253 appears to favor Aβ clearance from the brain. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Serum NGAL levels are increased in DS and associated with distinct species of Aβ depending on the progression of dementia as diagnosed by baseline and follow-up clinical assessments. 5 key findings →
Participants: 67 Evidence: low
Full summary, score breakdown and related studies → Original source
BCG vaccine has been used for 100 years to prevent tuberculosis. 3 key findings →
Design: open-label trial Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a complex multifactorial disorder that poses a substantial burden on patients, caregivers, and society. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We identified the feasibility of a blood-based biomarker approach in AD diagnostics though the results warrant validation in large-scale studies. 3 key findings →
Participants: 90 Evidence: low
Full summary, score breakdown and related studies → Original source
Closing this gap will require the introduction of high-performing blood tests, greater reliance on cerebrospinal fluid (CSF) testing, and expansion of positron emission tomography (PET) capacity. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Red blood cells (RBCs) are characterized by a remarkable elasticity, which allows them to undergo very large deformation when passing through small vessels and capillaries. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A regular sleep-wake cycle plays a positive function that preserves synaptic plasticity and brain activity from neuropathological injuries. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We found that miR-150-5p expression was significantly upregulated in DAT compared to mild cognitive impairment and healthy subjects. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
South Korea's healthcare infrastructure requires more preparation for the introduction of a disease-modifying therapy, with the primary capacity limitation being the low number of dementia specialists. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Insulin-like growth factor-1 (IGF-1) function declines with age and is associated with brain ageing and the progression of age-related neurological conditions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Baseline data are publicly available; treatment data and biological samples, including baseline and treatment-related blood-based biomarker data will become available in accordance with our original trial agreement and subsequently developed Collaboration for Alzheimer's Prevention principles. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is an irreversible neurodegenerative disease with clinical symptoms of memory loss and cognitive impairment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Elecsys β-amyloid (1-42) assay has high analytical performance that may improve biomarker-based AD diagnosis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The aim of the present study was to investigate, in patients with Alzheimer's disease (AD), and vascular dementia (VAD), patterns of local release of vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-beta), two cytokines having a pivotal role in hypoxia-induced angiogenesis. 3 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Immune privilege of the central nervous system (CNS) has been ascribed to the presence of a blood-brain barrier and the lack of lymphatic vessels within the CNS parenchyma. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by extracellular amyloid β (Aβ) and intraneuronal tau protein aggregations. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Human cerebrospinal fluid (CSF), produced by the choroid plexus and secreted into the brain ventricles and subarachnoid space, plays critical roles in intra-cerebral transport and the biophysical and immune protection of the brain. 2 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
The study demonstrates a moderate linear negative association between cerebral amyloid plaque load and CSF Abeta42 levels in AD patients in vivo and suggests possible regional differences of the association. 3 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 3,555 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →